Zepbound and Mounjaro Better Than Weight Loss Drugs Wegovy, Ozempic

As companies race to capture the weight loss drug market, which Goldman Sachs analysts predict will soon be worth $100 billion, one drug has a new advantage when it comes to shedding pounds, Danielle Chemtob reported for Forbes Daily.

Both drugs have been hailed as game changers for treating obesity—and both are in short supply.

New research shows that tirzepatide, the generic name for Zepbound and Mounjaro, was “associated with significantly greater weight loss” than semaglutide, the generic name for Wegovy and Ozempic, in overweight or obese adults.

The research is a boon for Zepbound, manufactured by pharma giant Eli Lilly, but that doesn’t mean it’s going to replace dominant player Novo Nordisk’s Wegovy anytime soon.

Both drugs have been hailed as game changers for treating obesity—and both are in short supply.